Latest news and press releases about Bristol-Myers Squibb Company (BMY): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19.
Price
| Price | $58.81 |
| Market Cap | $120.1B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 13.47 |
| Price / Book | 5.59 |
| EV / EBITDA | 9.56 |
| Dividend Yield | 4.12% |
Profitability
| Return on Equity | 46.75% |
| Return on Invested Capital | 15.47% |
| Return on Assets | 10.59% |
| Gross Margin | 70.16% |
| Operating Margin | 28.27% |
| Net Margin | 18.87% |
Related companies: CI · CVS · ELV · GSK · HCA · MCK · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of BMY: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks